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Abstract
Diabetes mellitus is rapidly becoming the world’s most dangerous serial killer. Type 1 diabetes (T1D) is a currently incurable autoimmune 
disease marked by progressive, and eventually exhaustive, destruction of the insulin-producing pancreatic beta cells. Type 2 diabetes 
(T2D) describes the combination of insulin resistance in peripheral tissue, insufficient insulin secretion from the pancreatic beta cells, 
and excessive glucagon secretion from the pancreatic alpha cells. T1D as well as severe cases of T2D are treated with insulin replacement, 
which can merely be considered as life support for the acute phases of the disease. Islet replacement of insulin-producing pancreatic 
beta cells represents a potential treatment method for both insulin-depleted diabetes (T1D) and insulin-resistant diabetes (T2D) and may 
shift diabetes management from life saving measures to a cure. One of the key challenges in islet transplants is the generation of reactive 
oxygen species (ROS) and the associated oxidative stress, which restricts graft longevity. A major leak of ROS takes place during oxidative 
phosphorylation at mitochondrial electron transport chain (ETC). Additionally, hyperglycemia-induced superoxide (O2•-) production has 
been linked to the development and progression of diabetic complications, both macrovascular and microvascular. Decreasing ROS in 
diabetic patients may prevent the incidence of long term diabetes complications. This review provides an overview of the role of mito-
chondria in diabetes, introducing them as a possible target for future treatment of diabetes.
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Introduction
The definite etiology of type 1 diabetes (T1D) is still obscure, 
but considered to root in a mixture of genetic predisposition 
and environmental factors, leading to continued autoimmuni-
ty.1 Five percent of diabetics have this type of diabetes.2 In 
Type 2 diabetes (T2D), peripheral tissue develops a resistance 
against insulin.3 T2D has been linked to "metabolic syndrome", 
which is defined by the International Diabetes Federation (IDF) 
as central obesity with two of the following: elevated blood 
pressure, elevated fasting plasma glucose, high serum triglyce-
rides, and low high-density cholesterol (HDL) levels (Available 
from: http://www.idf.org/metabolic-syndrome, updated 2014 
Oct 23; cited 2015 Jan 21). According to the Centers for Disease 
Control and Prevention (CDC), one out of three people will de-
velop T2D in their lifetime.2
The aims of diabetes management are primarily to save life in 
the short term and secondarily to prevent the development of 
diabetic complications in the long term. Both can be achieved 
by improving glycemic control, aiming for a glycated hemoglo-
bin (HbA1c) between 6.5%-7.0%.4 For patients with T1D, lifelong 
insulin replacement therapy marks the therapeutic objective 
for attaining glycemic control.5 In T1D, insulin dose varies be-
tween 0.4–0.8 UI/kg insulin a day.6 However, insulin adminis-
tration may induce hypoglycemic episodes that require hospi-
talization. The fear of hypoglycemia and the inconvenience of 
daily insulin injections cause many patients to neglect proper 
disease management and experience glycemic lability.7
For the management of T2D, lifestyle adjustments are consi-
dered the mainstay. If glycemic control fails to be obtained by 
lifestyle changes, treatment may resort to oral hypoglycemic 
agents (OHA), including biguanides, sulphonylureas, alpha glu-
cosidase inhibitors, and thiazolidinediones. In severe cases, 
insulin injections are required. If indicated, T2D patients need 
between 0.2–1.6 UI/kg of insulin a day.5 The current treatment 
options available for both types of diabetes merely delay the 
complications of the disease and do not provide a long-term 
solution.
Islet replacement of insulin-producing pancreatic beta cells 
represents a potential treatment method for both insulin-de-
pleted and insulin-resistant diabetes.8 Following islet transplan-
tation the patients benefit not only from a decrease of hypogly-
cemic events, but also spectacular improvement of HbA1c levels 
and stabilization of fasting blood glucose, without exposing 
themselves to the  risk of major surgery as in whole pancreas 
transplantation.8 A study by Barton and colleagues compared 
the efficacy of allogenic islet transplantation in T1D patients in 
different periods between 1999 and 2010.9 They analyzed 677 
T1D patients who had received islet transplants, with the aim 
to examine the differences in transplant efficacy between the 
early (1999-2002), mid (2003-2006), or recent (2007-2010) trans-
plant era. Three years following the islet replacement, insulin 
independence improved from 27% in the early era to 37% and 
44% in the mid and recent eras, respectively, at 36 months af-
ter transplantation. Barton and colleagues suggested that the 
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improvement of graft survival can be linked to more adequate 
means for preventing islet rejection.9 One of the key challenges 
in islet transplantation is the generation of reactive oxygen spe-
cies (ROS) and the associated oxidative stress.9 Oxidative stress 
occurs due to an imbalance between the intracellular free radical 
production and the cellular antioxidant defense mechanisms in 
the transplanted islets, which can lead to cell death. The cellular 
antioxidant defense mechanism comprises, among others, vita-
mins and minerals that are hence administered as supplements 
after organ transplantation.10 But why not directly target the chief 
generator of oxidative stress in our cells? Our mitochondria cons-
titute the major ROS generator, as ROS are released as a bypro-
duct of oxidative phosphorylation in the electron transport chain 
(ETC) of the inner mitochondrial membrane (IMM). 
This review provides an overview of the correlation between 
mitochondria and diabetes, introducing them as a target for 
future treatment of diabetes.
Search Strategy and Selection Criteria
A literature search was performed using MEDLINE MeSH terms 
“reactive oxygen species”, “alternative oxidase”, “mitochon-
drial DNA”, “diabetes mellitus”, “respiratory chain” and “oxi-
dative phosphorylation”. A total of 9807 articles were found. 
Following filtering based on selection criteria (publication wi-
thin last 20 years, English language, and the condition that 
at least 4 of the given terms must be in the same article), 7 
articles remained and an additional 13 articles were retrieved 
from references. This review follows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Sta-
tement.11
The Powerhouse of the Cell
Mitochondria are of prokaryotic origin and now the powerhou-
se in eukaryotic cells. The term was coined by a pioneer in 
modern cell biology, Philip Siekevitz, and reflects a critical role 
of the organelle, which is energy generation by aerobe degra-
dation of nutrients.10 Mitochondria are enclosed by a double 
membrane system, the outer mitochondrial membrane (OMM), 
and the inner mitochondrial membrane (IMM), each reflecting 
its function through its respective structure.12 
Metabolic energy is derived through a process known as oxida-
tive phosphorylation. The proteins required for this process are 
embedded in the IMM. The surface area that is required to ac-
commodate the proteins that participate in this process is pro-
vided by the configuration of the IMM into crista (Figure 1).12  
Substrate oxidation and adenosine triphosphate (ATP) produc-
tion [phosphorylation of adenosine diphosphate (ADP)] are 
coupled and commonly referred to as "oxidative phosphoryla-
tion".12 During oxidation, electrons are transferred from redu-
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Figure 1. The Mitochondrial Respiratory Chain.
Legend: The mitochondrial respiratory chain. The efflux of protons from the mitochondrial matrix into the intermembrane space establishes an electrochemical gradient. The back mo-
vement of protons down the electrochemical gradient is utilized by complex V/ATP Synthase (a proton channel) to phosphorylate ADP, and produce ATP. Oxidation and phosphorylation 
are coupled. The uncoupling of the processes can be achieved when uncoupling substances allow protons to pass through the IMM through an alternative pathway, without passing 
through complex V.13-14 This can be realized by the uncoupling protein thermogenin, which is present in brown adipose tissue. This alternative flow results in thermogenesis, the 
production of heat, rather than the ATP generation.15 In neonates, thermogenin-containing brown adipose tissue makes up to 5% of the body mass and is located primarily on the 
back. This can be explained evolutionarily, as the infant’s back was exposed to the environment during breast feeding and at higher risk of hypothermia.16 AOX provides an alternative 
pathway for electrons passing through the respiratory chain, directly converting O2 into H2O, bypassing complexes III and IV. Antimycin and cyanide, inhibitors of complex III and 
complex IV, respectively, are therefore ineffective during activation of AOX. Superoxide (O2•-) anions are produced when Coenzyme Q donates unpaired electrons to molecular oxygen.17 
The reaction between O2•- and NO produces peroxynitrite (ONOO•-). Hydrogen peroxide (H2O2) is converted into a hydroxyl radical (OH•). Both O2•- and ONOO•- are powerful oxidants.18 
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ced coenzymes (nicotinamide adenine dinucleotide in its redu-
ced form, NADH, and flavin adenine dinucleotide in its reduced 
form, FADH2) via the ETC to molecular oxygen as a final electron 
acceptor. The “chemiosmotic hypothesis” of oxidative phos-
phorylation postulates that during the electron movement, re-
leased energy is used by complexes I, III, and IV to facilitate 
the transport of protons from the matrix to the intermembrane 
space (IMS).19
The proton movement establishes an electrochemical proton 
gradient (delta Psi, δΨ) (180-190 mV negative to the cytosol),13 
that is subsequently equalized by H+ movement through a ga-
teway of the IMM – “ATP synthase”. Like in a watermill, the 
"molecular unit of currency” or ATP is generated by the move-
ment of protons down their electrochemical gradient through 
ATP Synthase.14
Oxidative Stress in Diabetes 
Oxidative stress makes up two crucial puzzle pieces of diabe-
tes. First, hyperglycemia-induced long-term complications of 
diabetes occur due to excessive production of ROS.20 Second, 
if scientists are successful in decreasing ROS generation after 
pancreatic islet replacement, prolonged graft survival could be 
ensured and diabetes treatment would shift from being life 
sustaining to achieving a cure. 
Glucose metabolism uses the Krebs cycle to generate NADH 
and FADH2, which donate electrons to complex I and complex 
II, respectively. These electrons are subsequently passed down 
the ETC to molecular oxygen as a final electron acceptor, a 
process which facilitates proton movement across the IMM. 
Glucose laden, diabetic cells exhibit a higher rate of glucose 
oxidation in the Krebs cycle, triggering more NADH and FADH2 
being shoved into the ETC and ultimately establishing a higher 
δΨ across the IMM. Eventually the electrical gradient will reach 
a threshold, and the electron transfer in complex III will be 
inhibited, resulting in the backup of electrons to coenzyme 
Q. Coenzyme Q then donates unpaired electrons to molecular 
oxygen, thereby generating the free radical O2•-.22
Under the influence of superoxide dismutase (SOD), O2•- can 
become a weaker ROS, hydrogen peroxide (H2O2).23 However, 
when O2•- reacts with nitric oxide (NO•) it may also be conver-
ted into the more active ROS peroxynitrate (ONOO-) (Figure 1).20 
Both O2•- and ONOO•- are powerful oxidants.23
Furthermore, hyperglycemia-induced O2•- generation in the 
mitochondria decreases the activity of glyceraldehyde-3 phos-
phate dehydrogenase (GAPDH), an enzyme that serves as the 
catalyst for the sixth step of glycolysis and is essential for glu-
cose production from glycogen breakdown (glycogenolysis).20,24 
The inhibition of GAPDH results in the accumulation of glyceral-
dehyde-3 phosphate, and the activation of the hyperglycemia 
pathways described hereafter in detail [protein kinase C (PKC) 
pathway; advanced glycation end-products (AGE) pathway].20 
The PKC pathway is initiated by the presence of a derivative 
of glyceraldehyde-3 phosphate, diacylglycerol (DAG). Excessive 
intracellular DAG stimulates PKC, a kinase protein that induces 
vascular endothelial growth factor (VEGF) expression in non-vas-
cular cells.25 VEGF is an essential angiogenesis factor and key 
to neovascularization. The VEGF-mediated neovascularization 
of the retina is a process known to play role in diabetic reti-
nopathy. In diabetic retinopathy, the genesis of friable vessels 
that frequently rupture results in hemorrhages that obscure 
the vision.26 VEGF also increases levels of transforming growth 
factor beta (TGF-ß), which is profibrinogenic and accelerates 
progression to glomerular sclerosis and hypertrophy, contribu-
ting to diabetic nephropathy (Figure 2).27
Another derivative of glyceraldehyde-3 phosphate, methylgl-
yoxal, activates the AGE pathway.22 The hyperglycemia-induced 
AGE pathway generates AGEs by non-enzymatic glycation of 
proteins. AGE production is irreversible, and circulating AGEs 
contribute as a deteriorating factor to vascular complications 
of diabetes patients.25
Circulating AGEs are involved in the trapping of albumin, 
low-density lipoprotein (LDL), immunoglobulins, and comple-
ment components. This procoagulating effect of AGEs is further 
increased by its function to deactivate NO•, which leads to the 
loss of the vasodilatory effect of NO. Besides, AGEs function as 
procoagulants themselves through increasing platelet adhesion 
and, at the same time, decreasing fibrinolysis. Also, AGE mole-
cules are capable of binding to RAGE receptors present on both 
macrophages and mesangial cells of the kidney. This binding 
stimulates the release of cytokines and growth factors, which 
results in inappropriate cell proliferation, collagen synthesis, 
and fibrosis in the glomeruli. Finally, AGEs spur lipid oxidation, 
which increases oxidative stress and favors inflammation.28
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Figure 2. Hyperglycemia: The Role of Protein Kinase C Activation in 
Diabetes Complications.21
Legend: Hyperglycemia-induced O2•- generation in the mitochondria leads to the accu-
mulation of glyceraldehyde-3 phosphate and its derivative DAG. Elevated intracellular 
DAG levels stimulate the PKC-mediated generation of VEGF, an angiogenesis factor that 
promotes neovascularization of retinal vessels. Unfortunately, the newly formed vessels 
are highly friable and would often rupture, resulting in hemorrhages that obscure the 
vision and destroy the retina (proliferative diabetic retinopathy). On the other hand, 
elevated levels of VEGF are responsible for simultaneously rising amounts of TGF-ß that 
spurs glomerular proliferation and sclerosis, eventually resulting in diabetic nephropathy 
(ROS = Reactive oxygen species; DAG = Diacylglycerol; PKC = Protein kinase C; VEGF = 
Vascular endothelial growth factor; TGF-ß = transforming growth factor beta).
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Many experiments demonstrated that the inhibition of AGEs 
slow down the developments of diabetic retinopathy in labo-
ratory rats.29 Hammes and coworkers treated 26-week-old Wis-
tar rats with aminoguanidine, an inhibitor of AGE formation. 
The induction of diabetes was achieved with an injection of 
streptozotocin in 0.05 M sodium citrate. The administration 
of aminoguanidine was initiated 2 weeks later. Advanced gly-
cosylation-specific fluorescence enabled the scientists to visua-
lize the amount of accumulated AGEs in the animals’ retinal 
vessels in the 26th and 75th week.  While no morphological 
changes and 170±15 fluorescence absorbance units were ob-
served in the healthy animals after 75 weeks, the diabetic rats 
had a high degree of neovascularization with friable vessels 
and 440±20 fluorescence absorbance units. The retinal vessels 
of those diabetic animals that had received aminoguanidine 
injections were less affected by these morphological changes, 
and glycosylation product-specific fluorescence measured was 
only 220±13.30 Although aminoguanidine has been under de-
velopment as a drug by the pharmaceutical company Alteon, 
clinical trials have been abandoned since 1998.31
The inhibition of GAPDH also results in the accumulation of the 
first and second glycolytic metabolites, glucose and fructose 
6-phosphate. Glucose is reduced by aldose reductase into sor-
bitol, which is further oxidized by the enzyme sorbitol dehy-
drogenase into fructose. This so-called polyol pathway leads to 
a decrease of reduced NADPH.26 NADPH is a crucial cofactor in 
redox reactions throughout the body, including the synthesis 
of myoinositol in the kidneys (Figure 3). Myoinositol deficien-
cy has been shown to be present in laboratory animals with 
induced diabetes as well as the sciatic nerve from deceased 
diabetic patients.26
Myoinositol is particularly important for the normal function of 
nerves. Already in 1987 it has been suggested by Salway and 
colleagues that myoinositol may prove valuable in preventing or 
delaying diabetic neuropathy. Neuropathy is marked by a slowed 
conduction velocity in peripheral and autonomic nerve fibers. 
Salway and his team, who had administered 500 mg myoinositol 
twice a day to seven different diabetes patients over a time span 
of two weeks, had observed an increased amplitude of the action 
potential of three different nerves (two in the lower extremity, 
one in the upper extremity). They suggested the possible value 
of myo-inositol in diabetes treatment in the future.30
In excess, ROS can activate several stress-sensitive intracellular 
signaling pathways (NF-kB, p38 MAPK, JNK/SAPK, and hexosami-
ne) that induce gene expression. The products of these genes 
are involved not only in the development of diabetes com-
plications, but also the development of insulin resistance.32,33 
For example, hyperglycemia-induced overproduction of O2•- 
diverts fructose-6-phosphate to the hexosamine pathway. The 
end product of the hexosamine pathway, UDP-N-acetylgluco-
samine is capable of glycating intracellular proteins, including 
transcription factors that alter gene expression (Available from: 
http://www.thepharmaletter.com/article/alteon-may-drop-pi-
magedine-in-niddm, updated 2014 Dec 21, cited 2015 Jan 21). 
This suggests that antioxidants could play a role in delaying 
and/or preventing the development of diabetes complications 
and insulin resistance, thereby immensely altering the pa-
thophysiology of T2D.
Alternative oxidase (AOX)
Alternative oxidase (AOX) is an integral mitochondrial mem-
brane enzyme which is mainly found in sessile organisms. 
It is capable of limiting the overproduction of mitochondrial 
ROS. However, this alternative pathway bypasses several pro-
ton-pumping steps, decreasing the pH and electrical gradients, 
thereby reducing the ATP generation. During the course of 
evolution, AOX has been lost from fast-moving organisms (in-
cluding humans), maybe due to the slight reduction in ATP 
production.34
By bypassing the respiratory chain, AOX confers resistance to cya-
nide and other inhibitors of the respiratory chain. Sessile animals, 
deep-sea organisms which are exposed to a hostile environment, 
thereby benefit from AOX and are still endowed with it.34
AOX provides a bypath of the ETC, thereby decreasing the O2•- ge-
neration and suppressing the infliction of oxidative damage on the 
cell. In the lab, AOX has been safely expressed in flies and human 
cells without eliciting any unwanted physiological side effects.34
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Figure 3. The Polyol Pathway in Hyperglycemia.35
Legend: Hyperglycemia stimulates the aldose reductase-mediated reduction of glucose into sorbitol (a polyol, hence polyol pathway). Aldose reductase utilizes cofactor 
NADPH, which results in a depletion of the antioxidant glutathione (GSH) and increases intracellular oxidative stress.31 Besides, NADPH is a crucial cofactor in redox 
reactions throughout the body, including the synthesis of myoinositol in the kidneys. Myoinositol deficiency has been identified in diabetic patients.36 Sorbitol is further 
oxidized to fructose. The generated NADH is subsequently converted by NADH oxidase into ROS and, therefore, acts as a booster for oxidative stress on the cell.37
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In 2013, C. intestinalis’ (a sessile sea squirt) AOX gene was suc-
cessfully expressed in mouse embryos with the help of germ 
line lentiviral transduction and subsequently passed down to 
the next generation.38 This so-called MitAOX mouse could be 
crossed with selective lines of diabetic mice, for example the 
non-obese diabetic (NOD) mice, an animal model for T1D. The 
resultant diabetic mice should have AOX incorporated in their 
genome. This AOX incorporation could be helpful to investigate 
hyperglycemia-induced overproduction of O2•- and its role in 
the development of diabetic complications.
Additionally, it has been suggested that AOX mitochondrial 
targeting sequence could be delivered with the aid of a viral 
vector, especially since recent data clearly points to the longe-
vity and safety of viral vectors.34 This injectable AOX has the 
potential to allow for therapeutic application in many disorders 
with marked overproduction of  O2•-.39
Oxidative stress is influencing the allograft outcome during the pe-
ritransplantation period of kidney transplant.38 In a study that Mo-
rales-Indiano and colleagues conducted on 131 patients with end 
stage renal disease (ESRD), both diabetic and non-diabetic patients 
had similar oxidative stress levels before kidney transplantation. 
However, measured oxidative stress was significantly higher in the 
diabetic patients after the intervention. In order to effectively me-
asure oxidative stress, Morales-Indiano and colleagues determined 
and measured oxidative stress markers both prior to and at 120 
days after grafting. The markers used to measure the generation of 
oxidative stress included anti-oxLDL antibodies (oxLDLab) and oxi-
dized LDL. The poorer allograft function in diabetics was attributed 
to elevated HbA1C, which promotes oxidative stress.17
In future, AOX injections may be administered to decrease 
hyperglycemia-induced oxidative stress in diabetic patients af-
ter transplant, including pancreatic islet transplants.
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